Isatuximab plus Pomalidomide and Dexamethasone in a Patient with Dialysis-Dependent Multiple Myeloma
- PMID: 34710867
- DOI: 10.1159/000519783
Isatuximab plus Pomalidomide and Dexamethasone in a Patient with Dialysis-Dependent Multiple Myeloma
Abstract
The phase 3 ICARIA-MM trial showed that the addition of isatuximab improved the progression-free survival compared with pomalidomide/dexamethasone. However, the safety and efficacy of isatuximab for end-stage renal failure remains unclear. A 67-year-old man who started hemodialysis 5 years ago for diabetic nephropathy was diagnosed with International Staging System stage III multiple myeloma (MM) of IgD-λ type 3 years ago. After receiving a total of 7 treatment regimens, his free light chain (FLC) λ level increased from 419 to 2,070 mg/L, indicating progressive disease. Twelve days after starting isatuximab plus pomalidomide (3 mg daily) and dexamethasone (IsaPd), his FLC λ level rapidly decreased to 412 mg/L. The patient has now completed 7 courses of IsaPd with no adverse events, including infusion reactions and neutropenia. Isatuximab requires a lower dilution volume than daratumumab and can be safely and effectively administered to hemodialysis-dependent MM patients.
Keywords: Antibody; Dialysis; Isatuximab; Multiple myeloma; Pomalidomide; Renal failure.
© 2021 S. Karger AG, Basel.
Similar articles
-
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis.Leuk Res. 2021 May;104:106576. doi: 10.1016/j.leukres.2021.106576. Epub 2021 Mar 29. Leuk Res. 2021. PMID: 33839618 Clinical Trial.
-
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14. Lancet. 2019. PMID: 31735560 Clinical Trial.
-
EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma.Oncologist. 2021 Nov;26(11):983-987. doi: 10.1002/onco.13892. Epub 2021 Jul 19. Oncologist. 2021. PMID: 34213061 Free PMC article. Clinical Trial.
-
An evaluation of isatuximab, pomalidomide and dexamethasone for adult patients with relapsed and refractory multiple myeloma.Expert Rev Hematol. 2021 May;14(5):419-427. doi: 10.1080/17474086.2021.1924052. Epub 2021 May 16. Expert Rev Hematol. 2021. PMID: 33945375 Review.
-
Isatuximab for the treatment of relapsed/refractory multiple myeloma.Expert Opin Biol Ther. 2020 Dec;20(12):1395-1404. doi: 10.1080/14712598.2021.1841747. Expert Opin Biol Ther. 2020. PMID: 33111607 Review.
Cited by
-
How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma.Cancers (Basel). 2022 Dec 27;15(1):155. doi: 10.3390/cancers15010155. Cancers (Basel). 2022. PMID: 36612152 Free PMC article. Review.
-
An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment.Ther Adv Hematol. 2022 Apr 2;13:20406207221088458. doi: 10.1177/20406207221088458. eCollection 2022. Ther Adv Hematol. 2022. PMID: 35392438 Free PMC article. Review.
-
The Role of Monoclonal Antibodies in the Treatment of Myeloma Kidney Disease.Pharmaceuticals (Basel). 2024 Aug 5;17(8):1029. doi: 10.3390/ph17081029. Pharmaceuticals (Basel). 2024. PMID: 39204135 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical